Canopy Growth Q1 FY2027: Revenue Climbs 13%, Loss Shrinks, but Acreage Default and Material Weakness Linger
CGC is trading near its 52-week low of $0.844 (14% above the low) on light trading volume (0.3× avg).
Summary
Canopy Growth's Q1 FY2027 revenue rose 13% to C$81.2M, while the net loss narrowed to C$14.6M. However, Acreage remains in default, a material weakness persists, and the loan agreement was amended to restrict certain share exchanges.
Key Events · Earnings and Guidance · CGC
-
Revenue Up 13%, Loss Narrows
Net revenue climbed to C$81.2M from C$72.1M a year ago, fueled by Canadian medical cannabis and the MTL acquisition. The net loss improved to C$14.6M from C$44.9M, aided by a C$16.2M non-cash fair value gain on Canopy USA investments.
-
Cash Burn Continues
Operating cash outflow widened to C$25.0M from C$10.3M a year ago. Cash and equivalents stood at C$336.6M at quarter-end, down from C$364.7M at March 31, 2026.
-
Acreage Default and Forbearance
Acreage remains in default under its credit agreement. A second forbearance agreement was entered into on July 31, 2026, with an outside date of January 31, 2027. The company warns it could lose its entire investment in Acreage and Wana debt if the senior lender enforces security.
-
Loan Agreement Amendment
On June 15, 2026, the Loan Agreement was amended to restrict Canopy Growth and certain subsidiaries from exchanging Non-Voting Shares into Canopy USA Class B Shares prior to the Stock Exchange Permissibility Date, limiting strategic options.
Analysis · CGC · Life Sciences
A 13% revenue jump to C$81.2 million and a sharply narrower net loss of C$14.6 million headline Canopy Growth's Q1 FY2027, buoyed by a C$16.2 million non-cash fair value gain on Canopy USA investments. Yet the company continues to burn cash—operating outflow hit C$25 million—and holds C$336.6 million in reserves. The filing confirms that Acreage remains in default under its credit agreement, with a forbearance now extended to January 2027, and that a material weakness in internal controls over financial reporting has not been remediated. Further constraining strategic flexibility, the Loan Agreement was amended to restrict exchanging Non-Voting Shares into Canopy USA Class B Shares. With a reverse stock split vote pending to maintain Nasdaq listing, these results reveal modest operational progress overshadowed by persistent financial and governance risks.
At the time of this filing, CGC was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415.3M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.